Striatal volume contributes to the prediction of onset of Huntington disease in incident cases
- PMID: 21907324
- PMCID: PMC3237730
- DOI: 10.1016/j.biopsych.2011.07.030
Striatal volume contributes to the prediction of onset of Huntington disease in incident cases
Abstract
Background: Previous neuroimaging research indicates that brain atrophy in Huntington disease (HD) begins many years before movement abnormalities become severe enough to warrant diagnosis. Most clinical trials being planned for individuals in the prediagnostic stage of HD propose to use delay of disease onset as the primary outcome measure. Although formulas have been developed based on age and CAG repeat length, to predict when HD motor onset will occur, it would be useful to have additional measures that can improve the accuracy of prediction of disease onset.
Methods: The current study examined magnetic resonance imaging (MRI) measures of striatum and white matter volume in 85 individuals prospectively followed from pre-HD stage through diagnosable motor onset (incident cases) and 85 individuals individually matched with incident cases on CAG repeat length, sex, and age, who were not diagnosed with HD during the course of the study.
Results: Volumes of striatum and white matter were significantly smaller in individuals who would be diagnosed 1 to 4 years following the initial MRI scan, compared with those who would remain in the pre-HD stage. Putamen volume was the measure that best distinguished between the two groups.
Conclusions: Results suggest that MRI volumetric measures may be helpful in selecting individuals for future clinical trials in pre-HD where HD motor onset is the primary outcome measure. In planning for multisite clinical trials in pre-HD, investigators may also want to consider using more objective measures, such as MRI volumes, in addition to onset of diagnosable movement disorder, as major outcome measures.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Data were presented as part of a talk at the International Neuropsychology Society in Boston, Feb 2–5, 2011. The title of the talk was “Neuroimaging in Pre-HD: Results from PREDICT-HD.”
All authors report no biomedical financial interests or potential conflicts of interest.
Figures

References
-
- The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971–983. - PubMed
-
- Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98. - PubMed
-
- Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53:1293–1296. - PubMed
-
- Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet. 1993;4:387–392. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical